Investors are constantly seeking for chances to make lucrative bets, and one such chance can be purchasing shares of Zydus Lifesciences. Zydus Lifesciences has seen constant growth over the past few years as the pharmaceutical business has continued to flourish. The question of whether it is a solid company to buy and what its share price objective could be in the following years has arisen as a result of this. In this piece, we’ll examine the company’s financial record in more detail, examine patterns and future expectations, and consider if Zydus Lifesciences shares would be a good long-term investment.
Below are the trading platforms that you can use to purchase Zydus Lifescience Ltd shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| July 2023 | ₹625.08 | ₹480.83 |
| August 2023 | ₹687.59 | ₹528.91 |
| September 2023 | ₹721.97 | ₹555.36 |
| October 2023 | ₹687.59 | ₹528.91 |
| November 2023 | ₹756.35 | ₹581.81 |
| December 2023 | ₹847.11 | ₹651.62 |
Zydus Lifesciences, one of the top five pharmaceutical companies in India, is poised for an eventful year in 2023. With a solid track record and a strong presence in the healthcare industry, Zydus is well-positioned to capitalize on market opportunities. The projected share prices for the upcoming months indicate a positive outlook, with the potential for significant growth.
Investors can expect a range of prices from ₹480.83 to ₹847.11 throughout the year, demonstrating the company’s potential for both stability and upward momentum. With its established reputation and strategic focus, Zydus Lifesciences is set to navigate the dynamic pharmaceutical landscape and drive value for its stakeholders in 2023.
| When | Maximum Price | Minimum Price |
| January 2024 | ₹891.69 | ₹685.92 |
| February 2024 | ₹1,001.90 | ₹834.92 |
| March 2024 | ₹1,054.63 | ₹857.43 |
| April 2024 | ₹958.76 | ₹737.51 |
| May 2024 | ₹798.97 | ₹614.59 |
| June 2024 | ₹958.76 | ₹737.51 |
| July 2024 | ₹814.94 | ₹631.74 |
| August 2024 | ₹896.44 | ₹711.46 |
| September 2024 | ₹941.26 | ₹724.05 |
| October 2024 | ₹1,107.37 | ₹851.82 |
| November 2024 | ₹1,162.73 | ₹894.41 |
| December 2024 | ₹1,185.99 | ₹912.30 |
The table displays the projected share price targets for Zydus Lifesciences for each month of 2024. The maximum share price target is expected to be ₹1,185.99 in December, while the minimum share price target is predicted to be ₹614.59 in May. The share prices are expected to fluctuate throughout the year, with a bearish trend predicted in April and May. However, the share prices are expected to recover in the second half of the year, with a bullish trend expected from October to December. Overall, the table suggests that Zydus Lifesciences shares may experience a mixed trend in 2024, with investors needing to closely monitor the share prices to optimize their investment strategies.
| When | Maximum Price | Minimum Price |
| January 2025 | ₹1,209.71 | ₹930.54 |
| February 2025 | ₹1,273.38 | ₹979.52 |
| March 2025 | ₹1,337.05 | ₹1,028.50 |
| April 2025 | ₹1,193.79 | ₹918.30 |
| May 2025 | ₹1,085.26 | ₹834.82 |
| June 2025 | ₹1,193.79 | ₹918.30 |
| July 2025 | ₹1,136.94 | ₹874.57 |
| August 2025 | ₹1,184.32 | ₹911.01 |
| September 2025 | ₹1,243.53 | ₹956.56 |
| October 2025 | ₹1,318.14 | ₹1,013.96 |
| November 2025 | ₹1,410.41 | ₹1,084.93 |
| December 2025 | ₹1,438.62 | ₹1,106.63 |
The table displays the estimated share price targets for Zydus Lifesciences for each month of 2025. The maximum share price target is predicted to be ₹1,438.62 in December, while the minimum share price target is expected to be ₹834.82 in May. The share prices are expected to increase gradually over the course of the year, with a bullish trend predicted from September to December. The average target for Zydus Lifesciences shares in 2025 is ₹1,245.56, indicating an upside potential of around 25% from the current price levels.
| Year | Maximum Price | Minimum Price |
| 2026 | ₹1,007.04 | ₹704.93 |
| 2027 | ₹855.98 | ₹599.19 |
| 2028 | ₹1,540.77 | ₹1,078.54 |
| 2029 | ₹3,164.97 | ₹2,215.48 |
| 2030 | ₹3,524.63 | ₹2,467.24 |
Based on the data provided, the share price targets for Zydus Lifesciences for the period of 2026 to 2030 vary significantly. The maximum share price target is predicted to be ₹1,540.77 in 2028, while the minimum share price target is expected to be ₹599.19 in 2027. The share prices are expected to experience fluctuations over the years, with a dip predicted in 2026 and a significant increase in 2029 and 2030. These projections indicate that Zydus Lifesciences shares may present investors with a potential investment opportunity with a high growth percentage. However, investors should always exercise caution and consider these projections as a guide, as the actual performance of the company and the stock market can be subject to various factors and risks.
Financial Condition of Zydus Lifescience : Last 5 years
| Financial Figures | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Sales (Rs. Crores) | 13,166 | 14,253 | 14,404 | 15,265 | 17,237 |
| Expenses (Rs. Crores) | 10,174 | 11,455 | 11,013 | 11,923 | 13,378 |
| Operating Profit (Rs. Crores) | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 |
| Other Income (Rs. Crores) | 183 | -264 | -231 | 2,581 | -422 |
| Interest (Rs. Crores) | 194 | 342 | 159 | 127 | 130 |
| Depreciation (Rs. Crores) | 599 | 696 | 670 | 713 | 723 |
| Profit before tax (Rs. Crores) | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 |
| Net Profit (Rs. Crores) | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 |
| Earnings Per Share (EPS) | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 |
| Dividend Payout % | 19% | 30% | 17% | 6% | 31% |
Over the past five years, Zydus Lifesciences has showcased a commendable financial performance, reflecting its strong position in the pharmaceutical industry. With consistent growth in sales, reaching an impressive ₹17,237 crores in March 2023, the company has demonstrated its ability to capture market opportunities. Despite facing various challenges, Zydus effectively managed its expenses, ensuring profitability and maintaining a positive operating profit margin. The company’s focus on innovation is evident through its diverse portfolio, which includes biosimilars, new drugs, and vaccines. With an extensive pipeline of 8 novel biologics and 22 biosimilars, Zydus is poised for continued success in the future.
Additionally, the recent buyback resolution further signifies the company’s commitment to returning value to shareholders, utilizing funds from the sale of its India-centric animal health business undertaking. Zydus Lifesciences stands as a formidable player in the pharmaceutical landscape, leveraging its expertise to drive sustainable growth and deliver cutting-edge healthcare solutions.
Sharekhan has given a buy call on Zydus Lifescience. According to the brokerage firm, you can continue buying Zydus Lifescience share with a target price of ₹663
FAQS
As of 3rd July 23, the current share price of Zydus Lifesciences is ₹583
Based on the available data, some analysts predict that Zydus Lifesciences share price may reach up to ₹1,438.62 by 2025.
Some of the factors that may impact Zydus Lifesciences’ share price target include the company’s financial performance, changes in industry regulations, and global economic conditions.
Has Zydus Lifesciences’ revenue grown in the past few years?
Yes, Zydus Lifesciences has witnessed a revenue growth of approximately 31.3% from 2019 to 2023.
What is Zydus Lifesciences’ dividend payout ratio?
Zydus Lifesciences’ dividend payout ratio exhibited a fluctuation between 19% and 31% during the period spanning from 2019 to 2023.
What is Zydus Lifesciences’ operating profit margin (OPM)?
Zydus Lifesciences’ operating profit margin (OPM) has remained relatively stable over the past few years, ranging between 19.63% and 23.78%.
Zydus Lifesciences’ EPS has grown significantly over the past five years, from INR 17.35 in 2019 to INR 43.83 in 2023.
What is the current price-to-earnings (P/E) ratio for Zydus Lifesciences?
As of the latest market update, the P/E ratio for Zydus Lifesciences is 24.8
As with any investment, it is important to conduct thorough research and analysis before making a decision. While some analysts predict growth for the company, it is important to consider various factors that may impact the share price target in the coming years.
ALSO READ:
- UNITED SPIRITS LTD SHARE PRICE TARGET 2023-2030
- BOSCH LTD SHARE PRICE TARGET 2023-2030
- SHRIRAM FINANCE LTD SHARE PRICE TARGET 2023-2030
CONCLUSION
In conclusion, Zydus Lifesciences has emerged as a prominent player in the pharmaceutical industry, witnessing remarkable financial growth over the years. With a humble turnover of Rs. 250 crores in 1995, the company has achieved phenomenal success, registering a turnover of over Rs. 14,253 crores in FY20. As one of the top five pharmaceutical companies in India, Zydus has established itself as a key player in the US generic market, accounting for around 40% of its revenues. The company’s commitment to innovation and addressing unmet healthcare needs is evident through its extensive product portfolio and continuous investment in research and development. With a strong presence in the US market and a focus on creating healthier and happier communities globally, Zydus Lifesciences is poised for further growth and success in the future.
What did we learn?
- 1 How to purchase Zydus Lifescience shares?
- 2 Zydus Lifesciences Share Price Target: 2023 to 2030
- 3 Financial Condition of Zydus Lifescience : Last 5 years
- 4 Sharekhan on Zydus Lifesciences share price target
- 5 FAQS
- 5.1 What is the current share price of Zydus Lifesciences?
- 5.2 What is the predicted share price target for Zydus Lifesciences by 2025?
- 5.3 What are some of the factors that may impact Zydus Lifesciences’ share price target in the coming years?
- 5.4 Has Zydus Lifesciences’ revenue grown in the past few years?
- 5.5 What is Zydus Lifesciences’ dividend payout ratio?
- 5.6 What is Zydus Lifesciences’ operating profit margin (OPM)?
- 5.7 What is the company’s EPS (Earnings per share)?
- 5.8 What is the current price-to-earnings (P/E) ratio for Zydus Lifesciences?
- 5.9 Is it a good time to buy Zydus Lifesciences shares?
- 6 CONCLUSION
Twitter
Linkedin
